Salivary galectin-3: a novel biomarker of pemphigus disease severity
Egyptian Journal of Dermatology and Venereology · 2026-05 · 46 (2) · 166-173
DOI: 10.4103/ejdv.ejdv_51_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Egyptian Journal of Dermatology and Venereology, online erschienen am 06.05.2026. Verfasst von Eman Fathy und 3 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Pemphigus is an immune-mediated bullous skin disorder that can be fatal. It is typified by flaccid blisters and erosions of the skin and mucous membranes. The majority of pemphigus patients develop an immunoglobulin E autoantibody response. Galectin-3 (Gal-3) and soluble CD23 are the two primary components of the immunoglobulin E. It is unclear exactly what role Gal-3 plays in pemphigus disease. One of the vital body fluids that can indicate a person’s illness or normal internal features is saliva. Neither the serum nor salivary Gal-3 roles have been identified in pemphigus.
Objectives
We aimed to measure the serum and salivary levels of Gal-3 in pemphigus patients and to find out if there are any relationships between their levels and the Autoimmune Bullous Skin Disease Intensity Score, which measures disease activity. Patients and methods Thirty patients with a confirmed diagnosis of pemphigus disease and 30 healthy controls were enrolled. Human Gal-3 enzyme-linked immunosorbent assay was used to measure Gal-3 levels in serum and saliva.
Results
A statistically significant increase in serum and salivary Gal-3 levels among cases (mean±SD: 18.58±3.50 and 117.09±32.83) relative to healthy controls (mean±SD: 6.69±1.92 and 93.06±26.60; P
Zitieren
APA
Fathy, E., Shehata, K. M. A., Kamal, A. A., & Hassan, H. (2026). Salivary galectin-3: a novel biomarker of pemphigus disease severity. Egyptian Journal of Dermatology and Venereology, 46(2), 166-173. https://doi.org/10.4103/ejdv.ejdv_51_25
Vancouver
Fathy E, Shehata KMA, Kamal AA, Hassan H. Salivary galectin-3: a novel biomarker of pemphigus disease severity. Egyptian Journal of Dermatology and Venereology. 2026;46(2):166-173. doi:10.4103/ejdv.ejdv_51_25
BibTeX
@article{Fathy2026,
author = {Fathy, Eman and Shehata, Khaled Mohamed Ali and Kamal, Asmaa A. and Hassan, Heba},
title = {Salivary galectin-3: a novel biomarker of pemphigus disease severity},
journal = {Egyptian Journal of Dermatology and Venereology},
year = {2026},
volume = {46},
number = {2},
pages = {166--173},
doi = {10.4103/ejdv.ejdv_51_25}
}
EUVIMED